カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の慢性閉塞性肺疾患治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Chronic Obstructive Pulmonary Disease Therapeutics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19232）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19232
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：106
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の慢性閉塞性肺疾患治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

慢性閉塞性肺疾患治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の慢性閉塞性肺疾患治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

慢性閉塞性肺疾患治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・抗炎症薬、気管支拡張薬、その他

用途別セグメントは次のように区分されます。
・総合病院、専門クリニック

世界の慢性閉塞性肺疾患治療薬市場の主要な市場プレーヤーは以下のとおりです。
・Abbott、Akorn、AbbVie、AstraZeneca、Boehringer Ingelheim、Cipla、GSK、Merck、Mylan、Novartis、Pfizer、Roche、Teva、Vectura

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、慢性閉塞性肺疾患治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な慢性閉塞性肺疾患治療薬メーカーの企業概要、2019年～2022年までの慢性閉塞性肺疾患治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な慢性閉塞性肺疾患治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別慢性閉塞性肺疾患治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの慢性閉塞性肺疾患治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での慢性閉塞性肺疾患治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および慢性閉塞性肺疾患治療薬の産業チェーンを掲載しています。
・第13、14、15章では、慢性閉塞性肺疾患治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 慢性閉塞性肺疾患治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：抗炎症薬、気管支拡張薬、その他
- 用途別分析（2017年vs2021年vs2028年）：総合病院、専門クリニック
- 世界の慢性閉塞性肺疾患治療薬市場規模・予測
- 世界の慢性閉塞性肺疾患治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Abbott、Akorn、AbbVie、AstraZeneca、Boehringer Ingelheim、Cipla、GSK、Merck、Mylan、Novartis、Pfizer、Roche、Teva、Vectura
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：抗炎症薬、気管支拡張薬、その他
・用途別分析2017年-2028年：総合病院、専門クリニック
・慢性閉塞性肺疾患治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・慢性閉塞性肺疾患治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・慢性閉塞性肺疾患治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・慢性閉塞性肺疾患治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・慢性閉塞性肺疾患治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Chronic Obstructive Pulmonary Disease Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chronic Obstructive Pulmonary Disease Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. General Hospitals accounting for % of the Chronic Obstructive Pulmonary Disease Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Anti-inflammatory Drugs segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Chronic Obstructive Pulmonary Disease Therapeutics include Abbott, Akorn, AbbVie, AstraZeneca, and Boehringer Ingelheim, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Obstructive Pulmonary Disease Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Anti-inflammatory Drugs
Bronchodilators
Others
Market segment by Application can be divided into
General Hospitals
Specialty Clinics
The key market players for global Chronic Obstructive Pulmonary Disease Therapeutics market are listed below:
Abbott
Akorn
AbbVie
AstraZeneca
Boehringer Ingelheim
Cipla
GSK
Merck
Mylan
Novartis
Pfizer
Roche
Teva
Vectura
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chronic Obstructive Pulmonary Disease Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Chronic Obstructive Pulmonary Disease Therapeutics, with price, sales, revenue and global market share of Chronic Obstructive Pulmonary Disease Therapeutics from 2019 to 2022.
Chapter 3, the Chronic Obstructive Pulmonary Disease Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chronic Obstructive Pulmonary Disease Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Obstructive Pulmonary Disease Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Chronic Obstructive Pulmonary Disease Therapeutics.
Chapter 13, 14, and 15, to describe Chronic Obstructive Pulmonary Disease Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Chronic Obstructive Pulmonary Disease Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Anti-inflammatory Drugs
1.2.3 Bronchodilators
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 General Hospitals
1.3.3 Specialty Clinics
1.4 Global Chronic Obstructive Pulmonary Disease Therapeutics Market Size & Forecast
1.4.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume (2017-2028)
1.4.3 Global Chronic Obstructive Pulmonary Disease Therapeutics Price (2017-2028)
1.5 Global Chronic Obstructive Pulmonary Disease Therapeutics Production Capacity Analysis
1.5.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Total Production Capacity (2017-2028)
1.5.2 Global Chronic Obstructive Pulmonary Disease Therapeutics Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Obstructive Pulmonary Disease Therapeutics Market Drivers
1.6.2 Chronic Obstructive Pulmonary Disease Therapeutics Market Restraints
1.6.3 Chronic Obstructive Pulmonary Disease Therapeutics Trends Analysis
2 Manufacturers Profiles
2.1 Abbott
2.1.1 Abbott Details
2.1.2 Abbott Major Business
2.1.3 Abbott Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.1.4 Abbott Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Akorn
2.2.1 Akorn Details
2.2.2 Akorn Major Business
2.2.3 Akorn Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.2.4 Akorn Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.3.4 AbbVie Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.4.4 AstraZeneca Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.5.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Cipla
2.6.1 Cipla Details
2.6.2 Cipla Major Business
2.6.3 Cipla Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.6.4 Cipla Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 GSK
2.7.1 GSK Details
2.7.2 GSK Major Business
2.7.3 GSK Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.7.4 GSK Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Merck
2.8.1 Merck Details
2.8.2 Merck Major Business
2.8.3 Merck Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.8.4 Merck Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.9.4 Mylan Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.10.4 Novartis Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Pfizer
2.11.1 Pfizer Details
2.11.2 Pfizer Major Business
2.11.3 Pfizer Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.11.4 Pfizer Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Roche
2.12.1 Roche Details
2.12.2 Roche Major Business
2.12.3 Roche Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.12.4 Roche Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Teva
2.13.1 Teva Details
2.13.2 Teva Major Business
2.13.3 Teva Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.13.4 Teva Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Vectura
2.14.1 Vectura Details
2.14.2 Vectura Major Business
2.14.3 Vectura Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
2.14.4 Vectura Chronic Obstructive Pulmonary Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Chronic Obstructive Pulmonary Disease Therapeutics Breakdown Data by Manufacturer
3.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Chronic Obstructive Pulmonary Disease Therapeutics
3.4 Market Concentration Rate
3.4.1 Top 3 Chronic Obstructive Pulmonary Disease Therapeutics Manufacturer Market Share in 2021
3.4.2 Top 6 Chronic Obstructive Pulmonary Disease Therapeutics Manufacturer Market Share in 2021
3.5 Global Chronic Obstructive Pulmonary Disease Therapeutics Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Chronic Obstructive Pulmonary Disease Therapeutics Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Market Size by Region
4.1.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Region (2017-2028)
4.1.2 Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2017-2028)
4.2 North America Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028)
4.3 Europe Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028)
4.4 Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028)
4.5 South America Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028)
4.6 Middle East and Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Type (2017-2028)
5.2 Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Type (2017-2028)
5.3 Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Application (2017-2028)
6.2 Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Application (2017-2028)
6.3 Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2028)
7.2 North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2028)
7.3 North America Chronic Obstructive Pulmonary Disease Therapeutics Market Size by Country
7.3.1 North America Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Country (2017-2028)
7.3.2 North America Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2028)
8.2 Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2028)
8.3 Europe Chronic Obstructive Pulmonary Disease Therapeutics Market Size by Country
8.3.1 Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Country (2017-2028)
8.3.2 Europe Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2028)
9.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2028)
9.3 Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market Size by Region
9.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2028)
10.2 South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2028)
10.3 South America Chronic Obstructive Pulmonary Disease Therapeutics Market Size by Country
10.3.1 South America Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Country (2017-2028)
10.3.2 South America Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2028)
11.2 Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2028)
11.3 Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Market Size by Country
11.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Chronic Obstructive Pulmonary Disease Therapeutics and Key Manufacturers
12.2 Manufacturing Costs Percentage of Chronic Obstructive Pulmonary Disease Therapeutics
12.3 Chronic Obstructive Pulmonary Disease Therapeutics Production Process
12.4 Chronic Obstructive Pulmonary Disease Therapeutics Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Chronic Obstructive Pulmonary Disease Therapeutics Typical Distributors
13.3 Chronic Obstructive Pulmonary Disease Therapeutics Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Abbott Basic Information, Manufacturing Base and Competitors
Table 4. Abbott Major Business
Table 5. Abbott Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 6. Abbott Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Akorn Basic Information, Manufacturing Base and Competitors
Table 8. Akorn Major Business
Table 9. Akorn Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 10. Akorn Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. AbbVie Basic Information, Manufacturing Base and Competitors
Table 12. AbbVie Major Business
Table 13. AbbVie Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 14. AbbVie Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 16. AstraZeneca Major Business
Table 17. AstraZeneca Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 18. AstraZeneca Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 20. Boehringer Ingelheim Major Business
Table 21. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 22. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Cipla Basic Information, Manufacturing Base and Competitors
Table 24. Cipla Major Business
Table 25. Cipla Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 26. Cipla Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. GSK Basic Information, Manufacturing Base and Competitors
Table 28. GSK Major Business
Table 29. GSK Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 30. GSK Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Merck Basic Information, Manufacturing Base and Competitors
Table 32. Merck Major Business
Table 33. Merck Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 34. Merck Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Mylan Basic Information, Manufacturing Base and Competitors
Table 36. Mylan Major Business
Table 37. Mylan Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 38. Mylan Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Novartis Basic Information, Manufacturing Base and Competitors
Table 40. Novartis Major Business
Table 41. Novartis Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 42. Novartis Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Pfizer Basic Information, Manufacturing Base and Competitors
Table 44. Pfizer Major Business
Table 45. Pfizer Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 46. Pfizer Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 50. Roche Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Teva Basic Information, Manufacturing Base and Competitors
Table 52. Teva Major Business
Table 53. Teva Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 54. Teva Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Vectura Basic Information, Manufacturing Base and Competitors
Table 56. Vectura Major Business
Table 57. Vectura Chronic Obstructive Pulmonary Disease Therapeutics Product and Services
Table 58. Vectura Chronic Obstructive Pulmonary Disease Therapeutics Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 60. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 61. Market Position of Manufacturers in Chronic Obstructive Pulmonary Disease Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 62. Global Chronic Obstructive Pulmonary Disease Therapeutics Production Capacity by Company, (K Units): 2020 VS 2021
Table 63. Head Office and Chronic Obstructive Pulmonary Disease Therapeutics Production Site of Key Manufacturer
Table 64. Chronic Obstructive Pulmonary Disease Therapeutics New Entrant and Capacity Expansion Plans
Table 65. Chronic Obstructive Pulmonary Disease Therapeutics Mergers & Acquisitions in the Past Five Years
Table 66. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Region (2017-2022) & (K Units)
Table 67. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Region (2023-2028) & (K Units)
Table 68. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 69. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 70. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2022) & (K Units)
Table 71. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2023-2028) & (K Units)
Table 72. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 73. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 74. Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Type (2017-2022) & (US$/Unit)
Table 75. Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Type (2023-2028) & (US$/Unit)
Table 76. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2022) & (K Units)
Table 77. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2023-2028) & (K Units)
Table 78. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 79. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 80. Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Application (2017-2022) & (US$/Unit)
Table 81. Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Application (2023-2028) & (US$/Unit)
Table 82. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Country (2017-2022) & (K Units)
Table 83. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Country (2023-2028) & (K Units)
Table 84. North America Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 85. North America Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 86. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2022) & (K Units)
Table 87. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2023-2028) & (K Units)
Table 88. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2022) & (K Units)
Table 89. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2023-2028) & (K Units)
Table 90. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Country (2017-2022) & (K Units)
Table 91. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Country (2023-2028) & (K Units)
Table 92. Europe Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 93. Europe Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 94. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2022) & (K Units)
Table 95. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2023-2028) & (K Units)
Table 96. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2022) & (K Units)
Table 97. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2023-2028) & (K Units)
Table 98. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Region (2017-2022) & (K Units)
Table 99. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Region (2023-2028) & (K Units)
Table 100. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 101. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 102. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2022) & (K Units)
Table 103. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2023-2028) & (K Units)
Table 104. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2022) & (K Units)
Table 105. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2023-2028) & (K Units)
Table 106. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Country (2017-2022) & (K Units)
Table 107. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Country (2023-2028) & (K Units)
Table 108. South America Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 109. South America Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 110. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2022) & (K Units)
Table 111. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2023-2028) & (K Units)
Table 112. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2022) & (K Units)
Table 113. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2023-2028) & (K Units)
Table 114. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Region (2017-2022) & (K Units)
Table 115. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Region (2023-2028) & (K Units)
Table 116. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 117. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 118. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2017-2022) & (K Units)
Table 119. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Type (2023-2028) & (K Units)
Table 120. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2017-2022) & (K Units)
Table 121. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales by Application (2023-2028) & (K Units)
Table 122. Chronic Obstructive Pulmonary Disease Therapeutics Raw Material
Table 123. Key Manufacturers of Chronic Obstructive Pulmonary Disease Therapeutics Raw Materials
Table 124. Direct Channel Pros & Cons
Table 125. Indirect Channel Pros & Cons
Table 126. Chronic Obstructive Pulmonary Disease Therapeutics Typical Distributors
Table 127. Chronic Obstructive Pulmonary Disease Therapeutics Typical Customers
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disease Therapeutics Picture
Figure 2. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Type in 2021
Figure 3. Anti-inflammatory Drugs
Figure 4. Bronchodilators
Figure 5. Others
Figure 6. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Application in 2021
Figure 7. General Hospitals
Figure 8. Specialty Clinics
Figure 9. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales (2017-2028) & (K Units)
Figure 12. Global Chronic Obstructive Pulmonary Disease Therapeutics Price (2017-2028) & (US$/Unit)
Figure 13. Global Chronic Obstructive Pulmonary Disease Therapeutics Production Capacity (2017-2028) & (K Units)
Figure 14. Global Chronic Obstructive Pulmonary Disease Therapeutics Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Chronic Obstructive Pulmonary Disease Therapeutics Market Drivers
Figure 16. Chronic Obstructive Pulmonary Disease Therapeutics Market Restraints
Figure 17. Chronic Obstructive Pulmonary Disease Therapeutics Market Trends
Figure 18. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Manufacturer in 2021
Figure 19. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Manufacturer in 2021
Figure 20. Chronic Obstructive Pulmonary Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Chronic Obstructive Pulmonary Disease Therapeutics Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Chronic Obstructive Pulmonary Disease Therapeutics Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Region (2017-2028)
Figure 24. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Region (2017-2028)
Figure 25. North America Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028) & (USD Million)
Figure 26. Europe Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028) & (USD Million)
Figure 28. South America Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue (2017-2028) & (USD Million)
Figure 30. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Type (2017-2028)
Figure 31. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Type (2017-2028)
Figure 32. Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Type (2017-2028) & (US$/Unit)
Figure 33. Global Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Application (2017-2028)
Figure 34. Global Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Application (2017-2028)
Figure 35. Global Chronic Obstructive Pulmonary Disease Therapeutics Price by Application (2017-2028) & (US$/Unit)
Figure 36. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Type (2017-2028)
Figure 37. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Application (2017-2028)
Figure 38. North America Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Country (2017-2028)
Figure 39. North America Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Country (2017-2028)
Figure 40. United States Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Type (2017-2028)
Figure 44. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Application (2017-2028)
Figure 45. Europe Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Country (2017-2028)
Figure 46. Europe Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Country (2017-2028)
Figure 47. Germany Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Region (2017-2028)
Figure 56. China Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Type (2017-2028)
Figure 63. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Application (2017-2028)
Figure 64. South America Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Country (2017-2028)
Figure 65. South America Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Chronic Obstructive Pulmonary Disease Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Chronic Obstructive Pulmonary Disease Therapeutics in 2021
Figure 77. Manufacturing Process Analysis of Chronic Obstructive Pulmonary Disease Therapeutics
Figure 78. Chronic Obstructive Pulmonary Disease Therapeutics Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のハンセン病治療市場2022年：市場規模予測（～2028年）
  • 世界の治療用閉塞性睡眠時無呼吸装置市場2022年：市場規模予測（～2028年）
  • 世界の胃食道逆流症（GERD）治療装置市場2022年：市場規模予測（～2028年）
  • 閉塞性睡眠時無呼吸症候群治療用装置のグローバル市場展望 2023年-2029年：診断機器、治療機器
  • ブール病診断の世界市場2023年：血液検査、アレンテスト、血管造影、組織生検、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19232 )"世界の慢性閉塞性肺疾患治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Chronic Obstructive Pulmonary Disease Therapeutics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。